

1/17

Antibody	ELISA Binding (EC ₅₀ in pM)	
	H1 HA (A/Ca/07/09)	H3 HA (A/HK/4801/14)
FX-0-1-215	11.1	193.0
Exemplary anti-HA antibody	13.0	27.2

Antibody	Neutralization (IC ₅₀ in µg/mL) (A/HK/4801/14 H3N2)
FX-0-1-215	1.73
Exemplary anti-HA antibody	1.17

FIG. 1




FIG. 2




FIG. 3

3/17




FIG. 4A




FIG. 4B

4/17




FIG. 5A

5/17




FIG. 5B

6/17



FX-0-1-m3 binding to H3-HA*FX-0-1-m3 mutants binding*

FIG. 6

7/17




FIG. 7




FIG. 8

9/17

Small scale expression in Expi293 cells (µg/mL)

A		VH									
		3	4	5	6	7	8	9	10	11	12
VL	2	557	570	552	594	588	588	512	573	5	126
	3	534	516	519	482	561	588	522	527	9	149
	4	503	502	509	512	16	201	170	192	10	22
	5	538	519	546	542	216	439	199	212	8	54
	6	501	460	507	449	504	540	429	486	8	74
	7	197	200	156	200	214	523	201	187	3	24

FIG. 9A

Binding to H1 (A/Cali/09/2007) c value of 4PL fit in nM

B		VH									
		3	4	5	6	7	8	9	10	11	12
VL	2	1.90E-02	2.12E-02	2.31E-02	2.07E-02	1.35E-02	2.54E-02	2.38E-02	2.27E-02	2.32E-02	1.61E-02
	3	2.46E-02	2.30E-02	2.82E-02	2.47E-02	2.46E-02	2.18E-02	2.11E-02	2.56E-02	2.22E-02	9.27E-02
	4	2.75E-02	2.19E-02	2.85E-02	2.77E-02	2.03E-02	2.04E-02	1.86E-02	1.81E-02	2.44E-02	1.82E-02
	5	1.76E-02	2.40E-02	2.36E-02	2.55E-02	1.66E-02	2.12E-02	1.60E-02	1.42E-02	2.46E-02	5.46E-02
	6	2.68E-02	2.73E-02	3.17E-02	2.21E-02	2.39E-02	2.69E-02	2.52E-02	1.75E-02	2.54E-02	1.69E-02
	7	2.02E-02	2.09E-02	2.74E-02	2.51E-02	2.07E-02	3.18E-02	1.78E-02	2.35E-02	2.16E-02	1.81E-02

FIG. 9B

Binding to H3 (A/Brisbane/10/2007) c value of 4PL fit in nM

C		VH									
		3	4	5	6	7	8	9	10	11	12
VL	2	3.13E-02	1.07E-01	2.19E-02	1.08E-01	3.52E-01	3.87E-02	7.49E-02	4.12E-02	6.63E+01	8.89E+01
	3	3.86E-02	4.35E-01	3.45E-02	3.39E-01	5.52E-01	2.86E-02	1.21E-01	8.24E-02	7.24E+01	1.35E+02
	4	4.50E-02	8.43E-02	2.68E-02	1.11E-01	1.45E-01	3.26E-02	6.08E-02	2.41E-02	1.12E+02	1.40E+02
	5	5.29E-01	1.76E+00	1.83E-01	2.82E+00	1.18E+00	1.19E-01	7.72E-01	1.88E-01	7.12E+01	1.55E+02
	6	3.13E-02	1.09E-01	2.95E-02	1.27E-01	2.74E-01	2.61E-02	9.61E-02	6.95E-02	1.54E+01	5.83E+01
	7	3.37E-02	2.26E-01	3.59E-02	1.86E-01	2.18E-01	3.56E-02	8.63E-02	8.93E-02	6.15E+01	1.36E+02

FIG. 9C

11/17




FIG. 10

12/17




FIG. 11

13/17

Antibody	EC50	VH	74	75	76
FX-0-1-m3	20.4	VH-0	S	K	N
FX-9-4-m3	9.6	VH-9	S	K	S
FX-123-4-m3	8.7	VH-123	S	K	S
FX-147-24-m3	21.6	VH-147	S	K	N
FX-148-24-m3	4.3	VH-148	S	K	L
FX-149-24-m3	4.6	VH-149	S	K	W
FX-150-24-m3	12.4	VH-150	S	K	F
FX-151-24-m3	16.8	VH-151	Y	K	S
FX-152-24-m3	9.1	VH-152	W	K	S
FX-153-24-m3	10.0	VH-153	S	Y	S
FX-154-24-m3	5.5	VH-154	S	W	S

FIG. 12




FIG. 13




FIG. 14




FIG. 15

17/17




FIG. 16